Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | TNFSF11 | O14788 | 2/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1157055 | 0.84 | ALDH1A1 (0.45) | LMNAALDH1A1KMT2AHTTMEN1 | |
| SCHEMBL29262662 | 0.82 | LMNA (0.50) | LMNAALDH1A1KMT2AGAAHTT | |
| SCHEMBL1156716 | 0.81 | MET (0.41) | ALDH1A1METMAPT | |
| SCHEMBL1156275 | 0.79 | BRD4 (0.42) | ALDH1A1MAPT | |
| SCHEMBL1580419 | 0.78 | KMT2A (0.47) | LMNAALDH1A1KMT2AGAAHTT | |
| SCHEMBL1156187 | 0.78 | KDM4E (0.51) | LMNAALDH1A1GAAHTTCA2 | |
| SCHEMBL1156254 | 0.78 | ALOX5 (0.44) | — | |
| SCHEMBL1155962 | 0.78 | ELAVL1 (0.45) | LMNAALDH1A1GAAHTTMAPT | |
| Hydrochloric Acid SCHEMBL1156764 | 0.77 | KMT2A (0.46) | LMNAALDH1A1KMT2AGAAHTT | |
| SCHEMBL1156247 | 0.77 | ALDH1A1 (0.45) | LMNAALDH1A1KMT2AGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308605-B2 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| EP-2336107-B1 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2015-09-23 | — | — | EP | disclosed |
| US-20140343070-A1 | PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-20 | — | — | US | disclosed |
| EP-1803709-B1 | PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-8048909-B2 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-01 | — | — | US | disclosed |
| EP-2336107-A2 | Proton pump inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-20110028476-A1 | PROTON PUMP INHIBITORS | KAJINO MASAHIRO | 2011-02-03 | — | — | US | disclosed |
| US-20080139639-A1 | 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-06-12 | — | — | US | disclosed |
| EP-1803709-A1 | PROTON PUMP INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2007-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343070-A1 | PROTON PUMP INHIBITORS | HRH2, HRH4, CYP2C19 | LMNA 3729/4885ALDH1A1 2529/4885KMT2A 2240/4885 |
| US-10308605-B2 | Proton pump inhibitors | HRH2, HRH4, HRH1 | LMNA 3457/4885ALDH1A1 2593/4885KMT2A 2262/4885 |
| US-20080139639-A1 | 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use | PTGER1, PTGER3, NR3C1 | LMNA 4165/4885ALDH1A1 1764/4885KMT2A 2049/4885 |
| US-20110028476-A1 | PROTON PUMP INHIBITORS | HRH2, HRH4, CYP2C19 | LMNA 3735/4885ALDH1A1 2505/4885KMT2A 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.